FILTER

FILTERED INTERVIEW RESULTS

Mining
Cote d’Ivoire
Ghana
MACIG

Jeff Quartermaine

CEO, PERSEUS MINING
Perseus Mining updates GBR on its three mines in West Africa.
Mining
Mali
MACIG

Larry Phillips

PRESIDENT AND CEO, COMPASS GOLD CORP
Compass Gold updates GBR on the exploration of its assets in Mali.
Mining
Peru

Gianflavio Carozzi

CEO, AESA
ASEA speaks of the importance of training to ensure safe and efficient operations.
Mining
Ghana
MACIG

Peter Quarm

DIRECTOR, DUTYLEX
Dutylex explains the challenges of beginning a business distributing industrial lubricants in Ghana and West Arica more generally.
Mining
Guinea
Cote d’Ivoire
Mali
Senegal
Ghana
Burkina Faso
MACIG

Martin van Gemert

MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Mining
Canada

Tim Gabruch

VP COMMERCIAL, DENISON MINES CHIEF COMMERCIAL OFFICER, URANIUM PARTICIPATION CORPORATION
Uranium Report 2020
“Phoenix is the highest-grade undeveloped uranium deposit in the world, with an average grade of 19.1% and 59.7 million pounds U3O8 in probable reserves (141,000 tonnes).”
Mining
Chile

Dave Lawson

PRESIDENT MINING & MINERALS, WOOD GROUP
Chile Mining 2020 EXPOMIN Official Investment Guide
Wood Group provides a winde array of mining services to its clients in Chile.
Mining
Peru
Canada
Namibia
Burkina Faso
MACIG

Ricus Grimbeek

PRESIDENT AND CEO, TREVALI
Trevali Mining examines the challenges of mining in the time of COVID-19 and how efforts to reduce costs have been rewarded.
Mining
Senegal
MACIG

Mike Brown

CEO, CHESSER RESOURCES
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.
Mining
Guinea
MACIG

Danny Callow

CEO, AFRICAN GOLD GROUP (AGG)
African Gold Group explains its ambitions in West Africa where it’s Kobada gold mine is under construction.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL